These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 25588366)

  • 21. Quantitative analysis of the effect of supersaturation on in vivo drug absorption.
    Takano R; Takata N; Saito R; Furumoto K; Higo S; Hayashi Y; Machida M; Aso Y; Yamashita S
    Mol Pharm; 2010 Oct; 7(5):1431-40. PubMed ID: 20704264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dissolution properties of co-amorphous drug-amino acid formulations in buffer and biorelevant media.
    Heikkinen AT; DeClerck L; Löbmann K; Grohganz H; Rades T; Laitinen R
    Pharmazie; 2015 Jul; 70(7):452-7. PubMed ID: 26373205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The influence of polymorphism on the manufacturability and in vitro dissolution of sulindac-containing hard gelatin capsules.
    Guadalupe Sánchez-González E; Yépez-Mulia L; Jesús Hernández-Abad V; Jung Cook H
    Pharm Dev Technol; 2015 May; 20(3):306-13. PubMed ID: 24417644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches.
    Fakes MG; Vakkalagadda BJ; Qian F; Desikan S; Gandhi RB; Lai C; Hsieh A; Franchini MK; Toale H; Brown J
    Int J Pharm; 2009 Mar; 370(1-2):167-74. PubMed ID: 19100319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biowaiver monographs for immediate release solid oral dosage forms: piroxicam.
    Shohin IE; Kulinich JI; Ramenskaya GV; Abrahamsson B; Kopp S; Langguth P; Polli JE; Shah VP; Groot DW; Barends DM; Dressman JB
    J Pharm Sci; 2014 Feb; 103(2):367-77. PubMed ID: 24301077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can dosage form-dependent food effects be predicted using biorelevant dissolution tests? Case example extended release nifedipine.
    Andreas CJ; Tomaszewska I; Muenster U; van der Mey D; Mueck W; Dressman JB
    Eur J Pharm Biopharm; 2016 Aug; 105():193-202. PubMed ID: 27322002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulating drug release profiles by lipid semi solid matrix formulations for BCS class II drug--an in vitro and an in vivo study.
    M K; Sistla R; Shastri NR
    Drug Deliv; 2015 May; 22(3):418-26. PubMed ID: 24471823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.
    Lennernäs H; Aarons L; Augustijns P; Beato S; Bolger M; Box K; Brewster M; Butler J; Dressman J; Holm R; Julia Frank K; Kendall R; Langguth P; Sydor J; Lindahl A; McAllister M; Muenster U; Müllertz A; Ojala K; Pepin X; Reppas C; Rostami-Hodjegan A; Verwei M; Weitschies W; Wilson C; Karlsson C; Abrahamsson B
    Eur J Pharm Sci; 2014 Jun; 57():292-9. PubMed ID: 24189462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of statistical analysis and Bayesian Networks in the evaluation of dissolution performance of BCS Class II model drugs.
    Wilson WI; Peng Y; Augsburger LL
    J Pharm Sci; 2005 Dec; 94(12):2764-76. PubMed ID: 16258987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of gastric pH, volume, and emptying on the food effect of ziprasidone oral absorption.
    Sutton SC; Nause R; Gandelman K
    AAPS J; 2017 Jul; 19(4):1084-1090. PubMed ID: 28321831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spray freeze drying with polyvinylpyrrolidone and sodium caprate for improved dissolution and oral bioavailability of oleanolic acid, a BCS Class IV compound.
    Tong HH; Du Z; Wang GN; Chan HM; Chang Q; Lai LC; Chow AH; Zheng Y
    Int J Pharm; 2011 Feb; 404(1-2):148-58. PubMed ID: 21094233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans.
    Shono Y; Jantratid E; Kesisoglou F; Reppas C; Dressman JB
    Eur J Pharm Biopharm; 2010 Sep; 76(1):95-104. PubMed ID: 20576487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predicting in vivo absorption behavior of oral modified release dosage forms containing pH-dependent poorly soluble drugs using a novel pH-adjusted biphasic in vitro dissolution test.
    Heigoldt U; Sommer F; Daniels R; Wagner KG
    Eur J Pharm Biopharm; 2010 Sep; 76(1):105-11. PubMed ID: 20472059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biowaiver monographs for immediate release solid oral dosage forms: acetaminophen (paracetamol).
    Kalantzi L; Reppas C; Dressman JB; Amidon GL; Junginger HE; Midha KK; Shah VP; Stavchansky SA; Barends DM
    J Pharm Sci; 2006 Jan; 95(1):4-14. PubMed ID: 16307451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New oral solid dosage form for furosemide oral administration.
    Perioli L; D'Alba G; Pagano C
    Eur J Pharm Biopharm; 2012 Apr; 80(3):621-9. PubMed ID: 22230797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A perspective for biowaivers of human bioequivalence studies on the basis of the combination of the ratio of AUC to the dose and the biopharmaceutics classification system.
    Sakuma S; Tachiki H; Uchiyama H; Fukui Y; Takeuchi N; Kumamoto K; Satoh T; Yamamoto Y; Ishii E; Sakai Y; Takeuchi S; Sugita M; Yamashita S
    Mol Pharm; 2011 Aug; 8(4):1113-9. PubMed ID: 21630662
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model.
    Wagner C; Jantratid E; Kesisoglou F; Vertzoni M; Reppas C; B Dressman J
    Eur J Pharm Biopharm; 2012 Sep; 82(1):127-38. PubMed ID: 22652546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved ziprasidone formulations with enhanced bioavailability in the fasted state and a reduced food effect.
    Thombre AG; Herbig SM; Alderman JA
    Pharm Res; 2011 Dec; 28(12):3159-70. PubMed ID: 21674263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Designing biorelevant dissolution tests for lipid formulations: case example--lipid suspension of RZ-50.
    Jantratid E; Janssen N; Chokshi H; Tang K; Dressman JB
    Eur J Pharm Biopharm; 2008 Jun; 69(2):776-85. PubMed ID: 18226882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.